▮ DFV TERMINAL
--:--:-- UTC SIGN IN
F1 Terminal / PMHS

PMHS — Polomar Health Services, Inc.

—
OTC · Health Care · Pharmaceuticals · CIK 1265521 ·
Last close
$0.08
Market Cap
$2.24M
52W High
$0.49
52W Low
$0.07
ADV30
2,040
Next earnings
—
Polomar Health Services, Inc. operates as a retail compounding pharmacy in the United States. The company owns SlimRx, a weight loss focused online platform connects patients with licensed physicians to prescribe weight loss medications, such as semaglutide compounded with vitamin B-12 and/or metformin; Tofacitinib, it treats rheumatoid arthritis by inhibiting JAK to reduce inflammation and pain; Semaglutide GLP-1, which regulates blood sugar, appetite, and weight in diabetes management; and compounded erectile dysfunction medications inhalable sildenafil. It also includes dermatological formulations for the treatment of acne, alopecia areata, basal cell carcinoma, Becker's nevus, vitiligo, and other skin conditions. In addition, it provides prescription fulfillment services for third party web based tele-health platforms. The company is based in Los Angeles, California.

Quarterly Fundamentals

Revenues vs Net Income (last 4 Q)

Assets vs Liabilities (last 4 Q)

PeriodRevenuesGrossProfit OpIncomeNetIncomeAssets CashLiabilities
Mar 2026 1,005,519 550,489 -6,902 -25,377 516,600 87,818 1,762,118
Dec 2025 632,057 448,763 -8,942,714 -8,988,912 390,043 132,150 1,612,372
Sep 2025 6,163 4,323 -628,808 -649,775 9,269,726 38,854 1,503,130
Jun 2025 5,470 3,832 -563,333 -605,563 9,432,865 4,678 1,036,921

Cashflow TTM (yfinance, fills SEC gap)

Operating CF
$-316,042
Investing CF
$0
Financing CF
$274,529
CapEx
$-10,661
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-0.06
As of
2026-06-07

Balance + Analyst (yfinance extras)

Retained Earnings
$-13,637,645
Inventory
$208,981
Receivables
$170,851
ST Investments
—
EBIT TTM
$-10,141,757
Pretax Income TTM
$-10,269,627
Interest Exp TTM
$127,870
Analysts
—

Yahoo Snapshot (yfinance, live)

Total Revenue
$1,649,208
EBITDA
$-618,055
Free Cash Flow
$3,545,744
Enterprise Value
$3,371,305
Total Cash
$87,818
Total Debt
$824,938
Shares Out
28,053,090
Trailing EPS
$-0.37
Book Value
$-0.04
ROE
-297.8%
ROA
-122.8%
Div Yield
—

Annual Trend (SEC EDGAR, last 4y)

Revenues vs Net Income (last 4y)

FY endRevenuesOpIncome NetIncomeAssetsLiabilities EquityOCF
Dec 2025 648,231 -10,550,264 -10,701,105 390,043 1,612,372 — -395,995
Dec 2024 58,824 -1,299,496 -1,341,333 9,951,773 1,352,642 — -1,019,787
Dec 2023 41,844 -440,832 -587,997 107,099 151,635 — -534,307
Dec 2022 34,526 -181,453 -181,124 261,484 74,715 — -40,934

Peers — same industry

TickerNameMarket CapLastDaily %
LIFD LFTD PARTNERS INC. $2.22M $0.15 —
SHPH Shuttle Pharmaceuticals Holdings, Inc. $2.20M $3.76 —
BDRX Biodexa Pharmaceuticals Plc $2.29M $3.07 —
PRFX PRF Technologies Ltd. $2.16M $2.49 —
PKTX ProtoKinetix, Inc. $2.04M $0.01 —

Recent Insider Activity

No insider activity indexed for this ticker.
SEC EDGAR filings → · StockAnalysis.com → · OpenInsider →